Szamosfalvi Marton, Pino Christopher J, Humes H David
Innovative BioTherapies, Ann Arbor, MI 48108, USA.
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Medicina (Kaunas). 2025 Aug 23;61(9):1513. doi: 10.3390/medicina61091513.
This review examines the clinical data and basic science research to evaluate the potential of the Selective Cytopheretic Device (SCD) in mitigating Extracorporeal Membrane Oxygenation (ECMO)-associated inflammation. In brief, SCD is an immunomodulatory device used within extracorporeal blood circuits along with the use of citrate anticoagulation. SCD has been shown to be a novel, first-in-its-class device (being marketed as QUELimmune by SeaStar Medical), which is capable of the autologous processing of hyper-inflamed leukocytes to reduce systemic inflammation. Strong preclinical data gathered for SCD in the context of both Cardio-Pulmonary Bypass (CPB) as well as ECMO set the stage for SCD to be used in these life support circuits. ECMO played a crucial role during the COVID-19 pandemic, during a time period when SCD therapy was being evaluated in clinical trials, generating initial clinical data in this setting. SCD has also been utilized in the setting of pediatric acute kidney injury (AKI) and multiorgan dysfunction (MOD), where ECMO can be common.
本综述审视了临床数据和基础科学研究，以评估选择性血细胞去除装置（SCD）在减轻体外膜肺氧合（ECMO）相关炎症方面的潜力。简而言之，SCD是一种免疫调节装置，与枸橼酸盐抗凝一起用于体外血液回路。SCD已被证明是一种新型的同类首创装置（由海星医疗公司作为QUELimmune进行销售），它能够对高度炎症化的白细胞进行自体处理，以减轻全身炎症。在体外循环（CPB）以及ECMO背景下为SCD收集的有力临床前数据为SCD在这些生命支持回路中的应用奠定了基础。在COVID-19大流行期间，当SCD疗法正在临床试验中进行评估时，ECMO发挥了关键作用，并在此背景下产生了初步临床数据。SCD也已被用于小儿急性肾损伤（AKI）和多器官功能障碍（MOD）的情况，而ECMO在这些情况中可能较为常见。
